Home » Posts tagged 'rare diseases'
Tag Archives: rare diseases
Open Orphan’s (ORPH) Maurice Treacy Hosts Value the Markets Webinar
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Chief Commercial Officer, Maurice Treacy, will be hosting a webinar alongside Value the Markets on Wednesday 30th October 2019 at 19:00 (UK time).
Maurice Treacy will take the opportunity to update existing and potential shareholders on Open Orphan and will provide an insight on the Company’s Genomic Health Data platform, Europe’s first rare disease, advocacy-led genomic database. Maurice will also discuss how and why it is now so important for pharmaceutical companies to have access to patient data when developing new drugs.
For those wishing to join, the webinar will be available through webcast or dial-in facilities via the details provided below:
Webcast URL Link:
https://vtm.clickmeeting.com/orph
Dial-in details:
UK dial-in number: +44 (20) 7048 4146
Irish dial-in number: +353 (76) 680 3062
Participant PIN: 214883#
When prompted, please provide participant’s pin code followed by # key
Enquiries:
Open Orphan Plc Tel: +353 (0)1 6440007
Cathal Friel, Chief Executive Officer
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Billy Clegg / Daniel Sherwen
Notes to Editors:
Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
Open Orphan (ORPH) – CRUX Asset Management Ltd increase Holding(s) in Company
TR-1: Standard form for notification of major holdings
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: |
Open Orphan PLC |
|||||
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) |
||||||
|
Non-UK issuer |
||||||
|
2. Reason for the notification (please mark the appropriate box or boxes with an “X”) |
||||||
|
An acquisition or disposal of voting rights |
X |
|||||
|
An acquisition or disposal of financial instruments |
||||||
|
An event changing the breakdown of voting rights |
||||||
|
Other (please specify)iii: |
||||||
|
3. Details of person subject to the notification obligationiv |
||||||
|
Name |
CRUX Asset Management Ltd |
|||||
|
City and country of registered office (if applicable) |
London, UK |
|||||
|
4. Full name of shareholder(s) (if different from 3.)v |
||||||
|
Name |
FP CRUX UXITS OEIC |
|||||
|
City and country of registered office (if applicable) |
London, UK |
|||||
|
5. Date on which the threshold was crossed or reachedvi: |
30/09/2019 |
|||||
|
6. Date on which issuer notified (DD/MM/YYYY): |
01/10/2019 |
|||||
|
7. Total positions of person(s) subject to the notification obligation |
||||||
|
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments |
Total of both in % (8.A + 8.B) |
Total number of voting rights of issuervii |
|||
|
Resulting situation on the date on which threshold was crossed or reached |
4.10% |
0% |
4.10% |
10,428,571 |
||
|
Position of previous notification (if applicable) |
3.52% |
N/A |
3.52% |
8,928,571 |
||
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii |
|||||||||
|
A: Voting rights attached to shares |
|||||||||
|
Class/type of ISIN code (if possible) |
Number of voting rightsix |
% of voting rights |
|||||||
|
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
|
GB00B9275X97 |
10,428,571 |
4.10% |
|||||||
|
SUBTOTAL 8. A |
10,428,571 |
4.10% |
|||||||
|
|
|||||||||
|
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights |
|||||
|
SUBTOTAL 8. B 1 |
|||||||||
|
|
|||||||||
|
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) |
|||||||||
|
Type of financial instrument |
Expiration |
Exercise/ |
Physical or cash settlementxii |
Number of voting rights |
% of voting rights |
||||
|
SUBTOTAL 8.B.2 |
|||||||||
|
|
|||||||||
|
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) |
||||
|
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii |
X |
|||
|
Full chain of controlled undertakings through which the voting rights and/or the |
||||
|
Namexv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
10. In case of proxy voting, please identify: |
||||
|
Name of the proxy holder |
||||
|
The number and % of voting rights held |
||||
|
The date until which the voting rights will be held |
||||
|
11. Additional informationxvi |
||||
|
Place of completion |
London, UK |
|
Date of completion |
01/10/2019 |
END